Liver study tests COVID drug safety in 16 volunteers
NCT ID NCT06568861
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study looked at how the experimental COVID-19 drug ALG-097558 behaves in people with moderate liver impairment compared to healthy adults. Sixteen participants took the drug twice daily, and researchers measured drug levels in the blood and monitored side effects. The goal was to understand dosing needs for liver-impaired patients, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.